FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386157158> ?p ?o ?g. }

• W4386157158 endingPage "4663" @default.
• W4386157158 startingPage "4652" @default.
• W4386157158 abstract "PURPOSE Financial toxicity (FT) affects 20% of cancer survivors and is associated with poor clinical outcomes. No large-scale programs have been implemented to mitigate FT. We evaluated the effect of monthly FT screening as part of a larger patient-reported outcomes (PROs) digital monitoring intervention. METHODS PRO-TECT (AFT-39) is a cluster-randomized trial of patients undergoing systemic therapy for metastatic cancer. Practices were randomly assigned 1:1 to digital symptom monitoring (PRO practices) or usual care (control practices). Digital monitoring consisted of between-visit online or automated telephone patient surveys about symptoms, functioning, and FT (single-item screening question from Functional Assessment of Chronic Illness Therapy-COmprehensive Score for financial Toxicity) for up to 1 year, with automated alerts sent to practice nurses for concerning survey scores. Clinical team actions in response to alerts were not mandated. The primary outcome of this planned secondary analysis was development or worsening of financial difficulties, assessed via the European Organisation for Research and Treatment of Cancer QLQ-C30 financial difficulties measure, at any time compared with baseline. A randomly selected subset of patients and nurses were interviewed about their experiences with the intervention. RESULTS One thousand one hundred ninety-one patients were enrolled (593 PRO; 598 control) at 52 US community oncology practices. Overall, 30.2% of patients treated at practices that received the FT screening intervention developed, or experienced worsening of, financial difficulties, compared with 39.0% treated at control practices ( P = .004). Patients and nurses interviewed stated that FT screening identified patients for financial counseling who otherwise would be reluctant to seek, or unaware of the availability of, assistance. CONCLUSION In this report of a secondary outcome from a randomized clinical trial, FT screening as part of routine digital patient monitoring with PROs reduced the development, or worsening, of financial difficulties among patients undergoing systemic cancer therapy." @default.
• W4386157158 created "2023-08-26" @default.
• W4386157158 creator A5000432344 @default.
• W4386157158 creator A5012303632 @default.
• W4386157158 creator A5021703509 @default.
• W4386157158 creator A5032886944 @default.
• W4386157158 creator A5039180386 @default.
• W4386157158 creator A5041669020 @default.
• W4386157158 creator A5044249374 @default.
• W4386157158 creator A5049049020 @default.
• W4386157158 creator A5059142577 @default.
• W4386157158 creator A5064707298 @default.
• W4386157158 creator A5068848162 @default.
• W4386157158 creator A5069643040 @default.
• W4386157158 creator A5070882104 @default.
• W4386157158 creator A5073710285 @default.
• W4386157158 creator A5086581232 @default.
• W4386157158 creator A5090009905 @default.
• W4386157158 creator A5091400921 @default.
• W4386157158 date "2023-10-10" @default.
• W4386157158 modified "2023-10-13" @default.
• W4386157158 title "Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39)" @default.
• W4386157158 cites W1598788265 @default.
• W4386157158 cites W1842042263 @default.
• W4386157158 cites W2059662906 @default.
• W4386157158 cites W2092216813 @default.
• W4386157158 cites W2098919693 @default.
• W4386157158 cites W2100550754 @default.
• W4386157158 cites W2115724268 @default.
• W4386157158 cites W2127604901 @default.
• W4386157158 cites W2129176838 @default.
• W4386157158 cites W2167571044 @default.
• W4386157158 cites W2192081476 @default.
• W4386157158 cites W2195040438 @default.
• W4386157158 cites W2228474255 @default.
• W4386157158 cites W2266198524 @default.
• W4386157158 cites W2292373964 @default.
• W4386157158 cites W2299539799 @default.
• W4386157158 cites W2529430742 @default.
• W4386157158 cites W2557299627 @default.
• W4386157158 cites W2620925856 @default.
• W4386157158 cites W2777219582 @default.
• W4386157158 cites W2799789594 @default.
• W4386157158 cites W2803984570 @default.
• W4386157158 cites W2943140853 @default.
• W4386157158 cites W3095896260 @default.
• W4386157158 cites W3109758094 @default.
• W4386157158 cites W3128973439 @default.
• W4386157158 cites W3151045310 @default.
• W4386157158 cites W3178062719 @default.
• W4386157158 cites W4281790169 @default.
• W4386157158 doi "https://doi.org/10.1200/jco.22.02834" @default.
• W4386157158 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37625107" @default.
• W4386157158 hasPublicationYear "2023" @default.
• W4386157158 type Work @default.
• W4386157158 citedByCount "1" @default.
• W4386157158 countsByYear W43861571582023 @default.
• W4386157158 crossrefType "journal-article" @default.
• W4386157158 hasAuthorship W4386157158A5000432344 @default.
• W4386157158 hasAuthorship W4386157158A5012303632 @default.
• W4386157158 hasAuthorship W4386157158A5021703509 @default.
• W4386157158 hasAuthorship W4386157158A5032886944 @default.
• W4386157158 hasAuthorship W4386157158A5039180386 @default.
• W4386157158 hasAuthorship W4386157158A5041669020 @default.
• W4386157158 hasAuthorship W4386157158A5044249374 @default.
• W4386157158 hasAuthorship W4386157158A5049049020 @default.
• W4386157158 hasAuthorship W4386157158A5059142577 @default.
• W4386157158 hasAuthorship W4386157158A5064707298 @default.
• W4386157158 hasAuthorship W4386157158A5068848162 @default.
• W4386157158 hasAuthorship W4386157158A5069643040 @default.
• W4386157158 hasAuthorship W4386157158A5070882104 @default.
• W4386157158 hasAuthorship W4386157158A5073710285 @default.
• W4386157158 hasAuthorship W4386157158A5086581232 @default.
• W4386157158 hasAuthorship W4386157158A5090009905 @default.
• W4386157158 hasAuthorship W4386157158A5091400921 @default.
• W4386157158 hasConcept C10138342 @default.
• W4386157158 hasConcept C126322002 @default.
• W4386157158 hasConcept C159110408 @default.
• W4386157158 hasConcept C162324750 @default.
• W4386157158 hasConcept C168563851 @default.
• W4386157158 hasConcept C1862650 @default.
• W4386157158 hasConcept C2780665704 @default.
• W4386157158 hasConcept C512399662 @default.
• W4386157158 hasConcept C535046627 @default.
• W4386157158 hasConcept C71924100 @default.
• W4386157158 hasConceptScore W4386157158C10138342 @default.
• W4386157158 hasConceptScore W4386157158C126322002 @default.
• W4386157158 hasConceptScore W4386157158C159110408 @default.
• W4386157158 hasConceptScore W4386157158C162324750 @default.
• W4386157158 hasConceptScore W4386157158C168563851 @default.
• W4386157158 hasConceptScore W4386157158C1862650 @default.
• W4386157158 hasConceptScore W4386157158C2780665704 @default.
• W4386157158 hasConceptScore W4386157158C512399662 @default.
• W4386157158 hasConceptScore W4386157158C535046627 @default.
• W4386157158 hasConceptScore W4386157158C71924100 @default.
• W4386157158 hasIssue "29" @default.
• W4386157158 hasLocation W43861571581 @default.
• W4386157158 hasLocation W43861571582 @default.

• next